Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders. The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.
The world radiopharmaceuticals market is expected to generate a revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine. Convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the Radiopharmaceuticals Industry include increasing incidence of cardiac patients and adoption of clear imaging technique, with the help of diagnostic equipment such as PET and SPECT. The factors that restrain the growth of the market include supply shortages, logistical difficulties, and limited number of trained medical personnel.
The report segments the radiopharmaceuticals industry on the basis of type, modality, application, end user, and geography. On the basis of type, the market is segmented into diagnostic, therapeutic, and research. Based on modality, the nuclear medicine market is segregated into SPECT, PET, alpha emitters, beta emitters, and brachytherapy. According to application, the market is classified into oncology, cardiology, neurology, thyroid, and others. The geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific is the highest revenue generating region accounting for about 35.1% of the total market and is projected to grow at a high CAGR of 8.4% during the forecast period.
Comprehensive competitive analysis and profiles of major market players such as Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., and IBA Group is also provided in this report.
View Full Reports Here :
KEY BENEFITS FOR STAKEHOLDERS:
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the world nuclear medicine market.
- This report includes a detailed quantitative analysis of the current market and estimations from 2014 to 2022, which contribute in identifying the key market opportunities for growth.
- Exhaustive analysis of the world radiopharmaceuticals market by type helps in understanding the types of radiopharmaceuticals that are currently being used along with the variants that would gain prominence in the future.
- Competitive intelligence (of leading manufacturers of radiopharmaceuticals) helps in understanding the competitive scenario across the geographies.
- Key market players within the radiopharmaceuticals market are profiled in this report and their strategies are analyzed thoroughly. This helps in understanding the competitive outlook of the global nuclear medicine market.
NEUCLEAR MEDICINE/ RADIOPAHRMACEUTICALS MARKET KEY SEGMENTS:
By Type Diagnostic
By Modality SPECT
By Application Oncology
- Central Nervous System
- PET & PET-CT
- Hospitals and diagnostic centers
- Research institutes
- North America
- Czech Republic
- Rest of Europe
- Rest of Asia-Pacific
- South Africa
- Rest of LAMEA
Chapter: 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
Chapter: 2 EXECUTIVE SUMMARY
2.1 CXO perspective
Chapter: 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.4 Clinical trials
3.5 Government regulations
3.6 Patent study
3.7 Market share analysis (2015)
3.8 Market dynamics
22.214.171.124 Increase in the number of new cancer cases
126.96.36.199 Rising adoption of SPECT and PET Scans
188.8.131.52 Increase in preference for radiotaion therapy for cancer treatment
184.108.40.206 Developments in imaging technologies using radiopharmaceuticals
220.127.116.11 Supply volatility, logistical challenges and stringent regulatory Policies
18.104.22.168 Competition from conventional alternative diagnostic procedures
22.214.171.124 Multilateral supply agreements between countries
126.96.36.199 Advances in neurological applications
Latest Reports :
About – Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Website : http://www.acutemarketreports.com
Company Name: Acute Market Reports
Contact Person: Chris Paul
Phone: India: +91 7755981103, Toll Free US/Canada: +1-855-455-8662
Address:Office No 01, 1st Floor, Aditi Mall, Baner